Background: Lung cancer screening with low-dose helical computed tomography (LDCT) can improve high-risk individuals’ chances of being diagnosed at an earlier stage and increase survival. Objectives: The aims of this article are to present the risk factors associated with the development of lung...

Background: Programmed death-1 (PD-1) immune checkpoint inhibitors are novel immuno-oncology agents. Unlike chemotherapy or targeted agents, which inhibit tumor cell proliferation or induce tumor cell death, immune checkpoint inhibitors are designed to stimulate a patient’s own immune system to...

Background: One of the largest, most expensive randomized, controlled trials, the National Lung Screening Trial, found that annual low-dose computed tomography (LDCT) scans led to a 20% reduction in lung cancer deaths. Objectives: This study describes the characteristics and program implementation...

Background: The development of targeted therapies has revolutionized the treatment of advanced non-small cell lung cancer (NSCLC), with new clinical trials and therapies consistently providing new information. This rapidly changing field mandates ongoing education for nursing professionals whose...